UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. _____)*

Aimmune Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

00900T107

(CUSIP Number)

December 31, 2015

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o  Rule 13d-1(b)

o  Rule 13d-1(c)

x  Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1) Consists of (i) 3,873,530 shares of Common Stock issued upon conversion of Series A convertible preferred stock of the Issuer in connection with its initial public offering, (ii) 3,248,600 shares of Common Stock issued upon conversion of Series B convertible preferred stock of the Issuer in connection with its initial public offering, and (iii) 312,500 shares of Common Stock acquired in the Issuer’s initial public offering. All such shares are held of record by LVPII (as defined below).

(2) Based on 42,249,431 shares of Common Stock outstanding as of October 31, 2015, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed by the Issuer with the Securities and Exchange Commission on November 4, 2015.

(1) Consists of (i) 3,873,530 shares of Common Stock issued upon conversion of Series A convertible preferred stock of the Issuer in connection with its initial public offering, (ii) 3,248,600 shares of Common Stock issued upon conversion of Series B convertible preferred stock of the Issuer in connection with its initial public offering, and (iii) 312,500 shares of Common Stock acquired in the Issuer’s initial public offering.

(2) Based on 42,249,431 shares of Common Stock outstanding as of October 31, 2015, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed by the Issuer with the Securities and Exchange Commission on November 4, 2015.

(1) Consists of (i) 118,270 shares of Common Stock subject to stock option awards that have been granted to Mr. Enright in his capacity as a director of the Issuer and are exercisable within 60 days after December 31, 2015, (ii) 3,873,530 shares of Common Stock issued upon conversion of Series A convertible preferred stock of the Issuer in connection with its initial public offering, (iii) 3,248,600 shares of Common Stock issued upon conversion of Series B convertible preferred stock of the Issuer in connection with its initial public offering, and (iv) 312,500 shares of Common Stock acquired in the Issuer’s initial public offering. All of the shares described in clauses (ii), (iii) and (iv) are held of record by LVPII (as defined below).

(2) Based on 42,367,701 shares of Common Stock, calculated as follows: (i) 118,270 shares of Common Stock subject to stock option awards that have been granted to Mr. Enright in his capacity as a director of the Issuer and are exercisable within 60 days after December 31, 2015, and (ii) 42,249,431 shares of Common Stock outstanding as of October 31, 2015, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed by the Issuer with the Securities and Exchange Commission on November 4, 2015.

(1) Consists of (i) 118,270 shares of Common Stock subject to stock option awards that have been granted to Mr. Enright in his capacity as a director of the Issuer and are exercisable within 60 days after December 31, 2015, (ii) 3,873,530 shares of Common Stock issued upon conversion of Series A convertible preferred stock of the Issuer in connection with its initial public offering, (iii) 3,248,600 shares of Common Stock issued upon conversion of Series B convertible preferred stock of the Issuer in connection with its initial public offering, and (iv) 312,500 shares of Common Stock acquired in the Issuer’s initial public offering. All of the shares described in clauses (ii), (iii) and (iv) are held of record by LVPII (as defined below).

(2) Based on 42,367,701 shares of Common Stock, calculated as follows: (i) 118,270 shares of Common Stock subject to stock option awards that have been granted to Mr. Enright in his capacity as a director of the Issuer and are exercisable within 60 days after December 31, 2015, and (ii) 42,249,431 shares of Common Stock outstanding as of October 31, 2015, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed by the Issuer with the Securities and Exchange Commission on November 4, 2015.

Aimmune Therapeutics, Inc.

8000 Marina Boulevard, Suite 300

Brisbane, California 94005

This Schedule 13G (the “Statement”) is being jointly filed by the following reporting persons (each a “Reporting Person” and collectively the “Reporting Persons”): Longitude Venture Partners II, L.P. (“LVPII”); LVPII’s general partner, Longitude Capital Partners II, LLC (“LCPII”); and LCPII’s managing members, Ms. Juliet Tammenoms Bakker and Mr. Patrick G. Enright.

The Reporting Persons have entered into a Joint Filing Agreement, dated January 29, 2016, a copy of which is filed as Exhibit A to this Statement, pursuant to which the Reporting Persons have agreed to file this Statement and all amendments thereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

The address of the principal business office of each Reporting Person is 800 El Camino Real, Suite 220, Menlo Park, California 94025.

LCPII is a limited liability company organized under the laws of the State of Delaware. LVPII is a limited partnership organized under the laws of the State of Delaware. Ms. Bakker and Mr. Enright are citizens of the United States of America.

Common Stock, par value $0.0001 per share (the “Common Stock”).

00900T107.

Not applicable.

See Row 9 of the cover page for each Reporting Person.*

See Row 11 of the cover page for each Reporting Person.**

See Row 5 of the cover page for each Reporting Person.*

See Row 6 of the cover page for each Reporting Person.*

See Row 7 of the cover page for each Reporting Person.*

See Row 8 of the cover page for each Reporting Person.*

* Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his, her or its pecuniary interest therein.

** The percentage of Common Stock reported as beneficially owned by each Reporting Person is based on 42,249,431 shares of Common Stock outstanding as of October 31, 2015, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed by the Issuer with the Securities and Exchange Commission on November 4, 2015

Not applicable.

The response to Item 2(a) of this Statement is incorporated herein by reference.

The response to Item 2(a) of this Statement is incorporated herein by reference.

Not applicable.

Not applicable.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 29, 2016

EXHIBIT INDEX

Exhibit 99.1:       Joint Filing Agreement, dated January 29, 2016, pursuant to Rule 13d-1(k)(1).

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the timely filing of such statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness or accuracy of the information concerning the others of the undersigned, except to the extent that it knows or has reason to believe that such information is inaccurate or incomplete. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Joint Filing Agreement as of January 29, 2016.